Acute Kidney Injury Clinical Trial
Official title:
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
The specific aim of this study is to evaluate the safety of non-steroidal anti-inflammatory
drugs (NSAIDs) and their impact on renal function and/or contribution to exercise-associated
hyponatremia (EAH) during an ultramarathon foot race. There is currently much debate over
whether NSAID ingestion during endurance events contributes to acute kidney injury. Endurance
events often ignite a "perfect storm" of physiologic insults- heat stress, dehydration, and
myopathy- which can all negatively impact kidney function. There is a concern that NSAIDs may
further potentiate these negative effects as well as contribute to EAH through its
anti-diuretic affect. To date, no powered, prospective study has ever examined the effects of
NSAIDs on either of these two biochemical outcomes
Ultramarathon endurance events, defined as any race longer than a marathon (26.2 miles), are
increasing in popularity, with a 10% increase in annual participants, and more than 69,000
finishers worldwide in 2013. Considerable literature has documented alterations in serum
biochemical profiles of these endurance athletes, with consistent evidence of elevated serum
creatinine (Cr) levels in healthy race finishers as well as those seeking medical care. While
acute renal failure in ultramarathon runners is a rare occurrence, acute kidney injury is
common, ranging from 34% in a single-stage ultramarathon to 55-80% in multi-stage
ultramarathons. The evidence is equivocal regarding NSAID ingestion and AKI. One study showed
that runners who ingested NSAIDs prior to marathons had greater post-race creatinine levels
than matched controls as well as higher rates of hospitalization and acute renal failure.
However, this contrasts with several other studies that showed a marked lack of difference in
creatinine levels or development of acute kidney injury between NSAID users and non-users
during ultramarathons. The only randomized trial to date on this subject found no difference
in serum creatinine levels between the NSAID and placebo groups at ultramarathon race end,
however conclusions were limited by a small unpowered sample size.
Exercise associated hyponatremia (EAH), defined as a serum sodium concentration below
135mEq/L, is recognized as a relatively common issue in endurance running events. The
incidence of EAH varies depending upon the distance of the race, with reported values of
3-28% for marathons, 23 - 38% for triathlons and 4-51% in single-stage ultramarathons. EAH is
likely under-diagnosed as athletes are often asymptomatic. While EAH most often manifests as
non-specific symptoms such as nausea, vomiting, dizziness, and fatigue, it can be a
potentially fatal disease that can progress to encephalopathy, seizures, pulmonary edema, and
death. There have been no large prospective studies examining the relationship between EAH
and NSAID ingestion.
This study will be conducted during the fifth stage of a 6-stage ultramarathon foot race that
covers a total of 250 kilometers. Data will be collected during four separate events over the
course of the coming year. All races are run by the RacingThePlanetā¢ 4-desert race series
with locations including: Jordan, Ecuador, China, and Chile. The evening after stage 4,
participants will be reminded to check in at the medical tent prior to stage 5 start, and at
that time the participants will be weighed and given their study drug packet (ibuprofen or
visually identical placebo). Approximately 80% of the finishers complete the 80-kilometer
Stage 5 in less than 19 hours, so the majority of participants will ingest 1600mg of
ibuprofen (400mg q 4 hours x 4 doses). The optimal adult dosing for analgesia is 400mg every
4 hours, with a maximum daily dose of 3200mg ((1999). Product information: Motrinā¢,
ibuprofen. Kalamazoo, MI, Pharmacia & Upjohn Company.)
Immediately after crossing the finish line of Stage 5, participants will be reweighed, then
seated in the study tent where a fingertip blood sample will be obtained via lancet and
capillary collection tube (Mock, Morrison, & Yatscoff, 1995) then analyzed for Na, Cr and BUN
(utilizing a Chem-8 cartridge) onsite immediately after collection using an iSTAT® point-of-
care analyzer (Abbott; East Windsor, NJ). Any participant who did not complete any stage
prior to stage 5 will be removed from the competition and the study. Both the point-of-care
device and the digital scale will be calibrated for prior to taking measurements. At this
point, the study is over and there is no further participant responsibilities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |